Aligned Genetics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aligned Genetics, Inc. - overview
Established
2008
Location
Anyang, Gyeonggi, South Korea
Primary Industry
Medical Devices & Equipment
About
Based in Gyeonggi-do, South Korea, and founded in 2008, Aligned Genetics, Inc. is a manufacturer of various bio-equipments and develops products based on biofusion technology. In May 2020, Aligned Genetics, Inc. raised approximately KRW 320 million in PIPE funding from investor Partners Investment.
In November 2023, Partners Investment sold 1,636 shares in Aligned Genetics, Inc. at KRW 12,000 per share for approximately KRW 19. 75 million. The company offers Logos Biosystems, a diverse range of bio-equipments featuring state-of-the-art technology.
The automatic cell counter, a standout product, reflects the company's dedication to efficiency and precision in biopharmaceutical research. Aligned Genetics leveraged bio-convergence technology and microfluidic control technology to create molecular diagnostic products. In addition, the Genescale solution facilitates point-of-care diagnosis for a range of infectious diseases and conducts mutation analysis on diverse biomarkers, including those associated with cancer and dementia.
Current Investors
Partners Investment
Primary Industry
Medical Devices & Equipment
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.alignedgenetics.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aligned Genetics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 4,095,688,104 | 4,711,533,808 | 5,636,108,190 | 5,675,117,364 | 7,793,683,150 | 7,957,134,013 | 11,761,977,467 | 13,752,579,320 | - | - | - |
| % Revenue Growth (YoY) | - | 15.0% | 19.6% | 0.7% | 37.3% | 2.1% | 47.8% | 16.9% | - | - | - |
| EBITDA (USD) | (119,298,455) | (1,290,891,635) | (1,121,593,054) | (1,436,471,968) | 317,439,248 | 422,593,167 | 2,717,526,480 | 3,499,379,145 | - | - | - |
| Operating Income (USD) | (357,402,391) | (1,596,922,113) | (1,541,046,890) | (1,923,885,767) | (398,924,306) | (253,476,359) | 2,178,935,858 | 2,849,002,252 | - | - | - |
| Operating Margin | (8.7%) | (33.9%) | (27.3%) | (33.9%) | (5.1%) | (3.2%) | 18.5% | 20.7% | - | - | - |
| % EBITDA Margin | (2.9%) | (27.4%) | (19.9%) | (25.3%) | 4.1% | 5.3% | 23.1% | 25.4% | - | - | - |
| NET Income (USD) | (261,356,375) | (1,555,619,602) | (1,754,366,246) | (1,588,097,025) | 116,738,344 | 468,234,116 | 5,541,665,889 | 2,332,756,887 | - | - | - |
| % Net Margin | (6.4%) | (33.0%) | (31.1%) | (28.0%) | 1.5% | 5.9% | 47.1% | 17.0% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.